

though a few long term remissions to etoposide–methotrexate–actinomycin-D or cisplatin–etoposide treatment have been reported.⁷

There are many lessons to be learnt from this unfortunate patient. Pathologists must always consider, especially in an unusual clinical setting, the possibility of a trophoblastic neoplasm, a potentially curable disease, before labelling a tumour as a high grade carcinoma or an incurable disease. For physicians, it underscores the fact that sound clinical judgement followed by good communication with the pathologist is the key to a correct diagnosis. Finally, it is a reminder that it is mandatory to take an obstetric history, even in apparently non-obstetric cases.

Sanjay A Pai

Department of Pathology, Manipal Hospital, Bangalore, India

Dinesh Kini

Department of Gastroenterology, Manipal Hospital, Bangalore, India

Ravi P Deo, Poonam U Patil

Department of Oncology, Manipal Hospital, Bangalore, India

Correspondence to: Dr Sanjay A Pai, Department of Pathology, Manipal Hospital, Airport Road, Bangalore 560017, India; sanjayapai@gmail.com

doi: 10.1136/jcp.2007.047217

Accepted 9 February 2007

Competing interests: None.

References

- 1 **Matthews TH**, Heaton GE, Christopherson WM. Primary duodenal choriocarcinoma. *Arch Pathol Lab Med* 1986;**110**:550–2.
- 2 **Ben-Arie A**, Piura B, Biran H, *et al*. Metastatic placental site trophoblastic tumors: clinical aspects of two unique cases. *Acta Obstet Gynecol Scand* 2001;**80**:672–3.
- 3 **Shih IM**, Kurman RJ. The pathology of intermediate trophoblastic tumors and tumor-like lesions. *Int J Gynecol Pathol* 2001;**20**:31–47.
- 4 **Hui R**, Maritza M, Parkash V. Gestational trophoblastic diseases: recent advances in histopathologic diagnosis and related genetic aspects. *Adv Anat Pathol* 2005;**12**:116–25.
- 5 **Behtash N**, Ghaemmaghami F, Hasanzadeh M. Long term remission of metastatic placental site trophoblastic tumor (PSTT: case report and review of literature). *World J Surg Oncol* 2005;**3**:34.

CORRECTIONS

doi: 10.1136/jcp.2006.043083corr1

Figure 4 of an article in the September issue should have been published in colour (Fukuzawa R, Heathcott RW, More HE, *et al*. Sequential *WT1* and *CTNNB1* mutations and alterations of β -catenin localisation in intralobar nephrogenic rests and associated Wilms tumours: two case studies. *J Clin Pathol* 2007;**60**:1013–16). Figure 4 is published in colour on our website at <http://jcp.bmj.com/supplemental>.

doi: 10.1136/jcp.2006.044644corr1

An article in the September issue was published with an incorrect title (Stój A, Rudzki Z, Stachura J, *et al*. The *JAK2* V617F mutation in Philadelphia-negative chronic myeloproliferative disorders. *J Clin Pathol* 2007;**60**:1070–1). The correct title should be: The *JAK2* V617F mutation is frequently present in buccal swabs from patients suffering from Philadelphia-negative chronic myeloproliferative disorders, who carry the mutation detected in bone marrow or peripheral blood cells.